Octreotide acetate

Octreotide acetate

1. Emergency treatment of esophageal-gastric varicose bleeding caused by liver cirrhosis, used in combination with special treatments (such as endoscopic sclerotherapy). 2. Prevention of complications after pancreatic surgery. 3. Relieve symptoms and signs related to gastrointestinal endocrine tumors. There is sufficient evidence to show that this product is effective for the following tumors: carcinoid tumors with carcinoid syndrome; VIP tumors; glucagonomas. The efficacy of this product for the following tumors is about 50% (the number of cases treated with this product so far is limited): gastrinoma/Zollinger-Ellison syndrome, insulinoma, and growth hormone releasing factor tumor. 4. It can control symptoms and reduce the concentration of growth hormone (GH) and growth hormone mediator C in patients with acromegaly who have failed surgery, radiotherapy or dopamine receptor agonists. It is also suitable for patients who cannot or do not

1. Continuous intravenous infusion of 0.025 mg/hour for esophageal-gastric varicose bleeding. The maximum treatment period is 5 days. It can be diluted with normal saline or glucose solution. 2. Prevention of complications after pancreatic surgery: 0.1 mg subcutaneous injection 3 times a day for 7 days. The first injection should be performed at least 1 hour before surgery. 3. The initial dose for gastrointestinal pancreatic endocrine tumors is 0.05 mg subcutaneous injection once or twice a day, and then the dose can be gradually increased to 0.2 mg three times a day based on tolerance and efficacy. 4. The initial dose for acromegaly is 0.05-0.1 mg subcutaneous injection once every 8 hours, and then the dose is adjusted based on monthly assessment of circulating GH concentration, clinical response and tolerance. The optimal dose for most patients is 0.2-0.3 mg/day, and the maximum dose should not exceed 1.5 mg/day. The dose can be reduced as appropriate after several months of treatment under the guidance of monitoring plasma GH levels. After 1 month of treatment with this product, if the GH concentration does not decrease and the clinical symptoms do not improve, the drug should be considered for discontinuation.

1. Local reactions to injection, including pain, a tingling or burning sensation at the injection site, accompanied by redness and swelling. These phenomena rarely last more than 15 minutes. Allowing the solution to reach room temperature before injection can reduce local discomfort. 2. Gastrointestinal reactions, including loss of appetite, nausea, vomiting, cramping abdominal pain, flatulence, loose stools, diarrhea, and steatorrhea. In rare cases, gastrointestinal reactions may resemble acute intestinal obstruction with progressive severe upper abdominal pain, abdominal tenderness, muscle tension, and abdominal distension. 3. Long-term use may lead to the formation of gallstones. 4. Because this product can inhibit the release of GH, glucagon, and insulin, it may cause blood sugar regulation disorders. Because it can reduce patients' postprandial glucose tolerance, a small number of long-term users may cause persistent hyperglycemia, and hypoglycemia has been observed. 5. Others: A few reports of acute pancreatitis occurred, which gradually disappeared after discontinuation of the drug. In rare cases, octreotide acetate treatment has been reported to cause hair loss in patients. Long-term use of this product and the development of gallstones may also cause pancreatitis. Some patients have liver dysfunction, including slowly onset hyperbilirubinemia with mild increases in alkaline phosphatase, γ-glutamyl transferase and transaminase.

Sealed storage